From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Dyshidrotic eczema can be effectively treated with a combination of self-care measures and medications, with topical corticosteroids such as betamethasone valerate 0.1% or clobetasol propionate 0.05% applied twice daily for 1-2 weeks being the first-line medical treatment for flare-ups.
Treatment Options
- For mild cases, start with frequent application of fragrance-free moisturizers and avoid known triggers like irritants, allergens, and excessive hand washing.
- Topical corticosteroids are the primary treatment for dyshidrotic eczema, with potent corticosteroids being more effective than mild ones, as shown in a study published in 1.
- For severe or persistent cases, a short course of oral prednisone (starting at 20-40mg daily with a taper over 2-3 weeks) may be necessary.
- Tacrolimus 0.1% or pimecrolimus 1% ointment can be used as steroid-sparing agents, especially for sensitive areas or long-term management.
Additional Therapies
- Severe cases might require phototherapy (UVB light) administered 2-3 times weekly for 6-8 weeks or oral immunosuppressants like cyclosporine (3-5mg/kg/day) for short periods.
- During acute flares, cold compresses can provide relief, and antihistamines like hydroxyzine (25mg three times daily) may help with itching.
- Preventing recurrence involves identifying and avoiding triggers, maintaining skin hydration, and using cotton-lined gloves for wet work.
Key Considerations
- A network meta-analysis published in 2 found that potent topical corticosteroids, tacrolimus 0.1%, and ruxolitinib 1.5% were among the most effective treatments for eczema.
- The same study found that mild topical corticosteroids, crisaborole 2%, and tapinarof 1% were among the least effective treatments.
- It is essential to weigh the benefits and risks of each treatment option, considering factors such as efficacy, safety, and potential side effects, as discussed in 1 and 2.